Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Last Updated: February 7, 2023

Details for Patent: 6,855,703

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 6,855,703
Title: Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
Abstract:A composition of matter is provided having a mixture of active estrogenic compounds. The mixture is present in chemically pure form. The mixture includes salts of conjugated estrone, conjugated equilin, conjugated .DELTA..sup.8,9 -dehydroestrone, conjugated 17.alpha.-estradiol, conjugated 17.alpha.-dihydroequilin, conjugated 17.beta.-dihydroequilin, conjugated 17.beta.-estradiol, conjugated equilenin, conjugated 17.alpha.-dihydroequilenin, and conjugated 17.beta.-dihydroequilenin. The mixture also contains the same essential estrogenic compounds present in naturally derived equine conjugated estrogens. Drug products including the composition of matter are also provided, as are methods of using these drug products to treat mammals in need of treatment. Methods of analyzing mixtures containing conjugated estrogens are also provided.
Inventor(s): Hill; Edward N. (Wilmington, NC), Leonard; Thomas W. (Wilmington, NC), Sancilio; Frederick D. (Wilmington, NC), Schlipp; Katherin M. (Wilmington, NC), Shirazi; Dean G. (Wilmington, NC), Whittle; Robert R. (Wilmington, NC)
Assignee: Endeavor Pharmaceuticals (Wilmington, NC)
Application Number:09/524,132
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,855,703
Patent Claim Types:
see list of patent claims
Composition; Use; Formulation;

Drugs Protected by US Patent 6,855,703

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,855,703

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2001245417 See Plans and Pricing
Australia 4541701 See Plans and Pricing
Canada 2402559 See Plans and Pricing
European Patent Office 1267852 See Plans and Pricing
Japan 2004500396 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.